TY - JOUR
T1 - Preferences in treating polyomavirus infection in kidney transplant recipients
T2 - A discrete choice experiment with patients, caregivers, and clinicians
AU - Chong, Chanel H.
AU - Wong, Germaine
AU - Au, Eric H.
AU - Scholes-Robertson, Nicole
AU - Muthuramalingam, Shyamsundar
AU - Roger, Simon D.
AU - Keung, Karen
AU - Jaure, Allison
AU - Teixeira-Pinto, Armando
AU - Howell, Martin
PY - 2024/12
Y1 - 2024/12
N2 - Background: Treatment strategies for BK polyomavirus (BKPyV) infection in kidney transplant recipients are heterogeneous among clinicians. We aimed to identify the treatment preferences of key stakeholders for BKPyV infection and measure the trade-offs between treatment outcomes.Methods: Adult kidney transplant recipients, caregivers, and clinicians were eligible to participate in a discrete choice experiment between February 2021 and June 2022. The five treatment-related attributes were achieving viral clearance and optimal graft function, as well as reducing the risk of graft loss, acute rejection, and complications. Results were analyzed using multinomial logistic models.Results: In total, 109 participants (57 kidney transplant recipients, 10 caregivers, and 42 health professionals) were included. The most important attribute was the risk of graft loss, followed by side effects and acute rejection. As the risk of graft loss increased, all participants were less inclined to accept an assigned treatment strategy. For instance, if graft loss risk was increased from 1% to 50%, the probability of uptake of a treatment strategy for BKPyV infection was reduced from 87% to 3%.Conclusion: Graft loss is the predominant concern for patients, caregivers, and health professionals when deciding on the treatment for BKPyV infection, and should be included in intervention trials of BKPyV infection. (Figure presented.).
AB - Background: Treatment strategies for BK polyomavirus (BKPyV) infection in kidney transplant recipients are heterogeneous among clinicians. We aimed to identify the treatment preferences of key stakeholders for BKPyV infection and measure the trade-offs between treatment outcomes.Methods: Adult kidney transplant recipients, caregivers, and clinicians were eligible to participate in a discrete choice experiment between February 2021 and June 2022. The five treatment-related attributes were achieving viral clearance and optimal graft function, as well as reducing the risk of graft loss, acute rejection, and complications. Results were analyzed using multinomial logistic models.Results: In total, 109 participants (57 kidney transplant recipients, 10 caregivers, and 42 health professionals) were included. The most important attribute was the risk of graft loss, followed by side effects and acute rejection. As the risk of graft loss increased, all participants were less inclined to accept an assigned treatment strategy. For instance, if graft loss risk was increased from 1% to 50%, the probability of uptake of a treatment strategy for BKPyV infection was reduced from 87% to 3%.Conclusion: Graft loss is the predominant concern for patients, caregivers, and health professionals when deciding on the treatment for BKPyV infection, and should be included in intervention trials of BKPyV infection. (Figure presented.).
KW - BK polyomavirus
KW - discrete choice experiment
KW - kidney transplant
KW - multinomial logistic model
KW - treatment preference
UR - http://www.scopus.com/inward/record.url?scp=85206930600&partnerID=8YFLogxK
U2 - 10.1111/tid.14390
DO - 10.1111/tid.14390
M3 - Article
AN - SCOPUS:85206930600
SN - 1398-2273
VL - 26
SP - 1
EP - 9
JO - Transplant Infectious Disease
JF - Transplant Infectious Disease
IS - 6
M1 - e14390
ER -